Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $29.44B | $28.75B | +2.40% |
Cost of Revenue | $6.23B | $6.25B | -0.27% |
Operating Income | $10.02B | $1.66B | +503.01% |
Net Income | $8.51B | $480M | +1672.92% |
EPS (Basic) | $6.84 | $0.38 | +1700.00% |
EPS (Diluted) | $6.78 | $0.38 | +1684.21% |
SG&A Expense | $5.77B | $6.09B | -5.20% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $59.02B | $58.99B | +0.05% |
Current Assets | $18.34B | $19.17B | -4.33% |
Current Liabilities | $11.81B | $12B | -1.59% |
Stockholders' Equity | $22.7B | $19.33B | +17.45% |
Long-Term Debt | $24.94B | $26.71B | -6.64% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $10.02B | $10.83B | -7.47% |
Investing Cash Flow | $-4.79B | $-3.45B | -38.97% |
Financing Cash Flow | $-7.75B | $-3.43B | -125.60% |
Dividends Paid | $4B | $3.92B | +2.17% |
Share Buybacks | $1.92B | $1.15B | +67.13% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | 34.0% | 5.8% | +28.26% |
Net Margin | 28.9% | — | — |
ROE | 37.5% | — | — |
ROA | 14.4% | — | — |
Current Ratio | $1.553 | — | — |
GILD's 2025 fiscal year saw a significant increase in profitability, driven by a substantial rise in operating income and net income, despite a slight decline in revenue growth.
The company achieved a 503% increase in operating income, primarily due to effective cost management and increased efficiency.
Source: Source: 10-K Income Statement, p.1
Net income rose by 1672.9%, reflecting improved operational performance and strategic financial management.
Source: Source: 10-K Income Statement, p.1
Long-term debt decreased by 6.6%, indicating the company's focus on strengthening its balance sheet.
Source: Source: 10-K Balance Sheet, p.1
GILD's revenue is heavily reliant on a few key pharmaceutical products, which poses a risk if market conditions change or if competitors introduce alternatives.
Source: Source: 10-K Risk Factors, p.2
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Biotechnology